1. Home
  2. CPBI vs TENX Comparison

CPBI vs TENX Comparison

Compare CPBI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Plains Bancshares Inc.

CPBI

Central Plains Bancshares Inc.

HOLD

Current Price

$21.00

Market Cap

81.4M

Sector

N/A

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$2.33

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPBI
TENX
Founded
2023
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.4M
71.1M
IPO Year
2023
2001

Fundamental Metrics

Financial Performance
Metric
CPBI
TENX
Price
$21.00
$2.33
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
1.6K
8.3M
Earning Date
06-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
9.38
N/A
EPS
0.39
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$53.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.56
$1.31
52 Week High
$21.83
$19.40

Technical Indicators

Market Signals
Indicator
CPBI
TENX
Relative Strength Index (RSI) 66.26 22.44
Support Level $16.88 $1.31
Resistance Level $21.83 $16.39
Average True Range (ATR) 0.15 0.32
MACD -0.02 -0.22
Stochastic Oscillator 95.06 6.57

Price Performance

Historical Comparison
CPBI
TENX

About CPBI Central Plains Bancshares Inc.

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: